✨
AI Summary
- Hansa Biopharma CEO discusses their lead asset for kidney transplants.
- The company's journey towards US FDA approval was detailed.
- Challenges faced during the completion of a Phase III program were shared.
Guests on This Episode
RA
Renee Aguiar-Lucander
1 podcast appearance